Improving agent for neuropathic pain

Abstract

An object of the present invention is to provide a substance which can be used as an active ingredient for improving neuropathic pain having a novel mechanism of action different from those of currently available agents and, therefore, provide an improving agent for neuropathic pain which rarely interacts with currently available agents and also does not have adverse reactions similar to those of currently available agents. An improving agent for neuropathic pain due to a hyperalgesic response of the present invention as a means for resolution is characterized by comprising, as an active ingredient, a lyase (an elimination enzyme) which has an activity of degrading a chondroitin sulfate chain of a chondroitin sulfate proteoglycan, and is typified by chondroitinase ABC which selectively removes chondroitin sulfate and dermatan sulfate of a proteoglycan.

1 . An improving agent for neuropathic pain due to a hyperalgesic response, comprising, as an active ingredient, a lyase having an activity of degrading a chondroitin sulfate chain of a chondroitin sulfate proteoglycan. 
     
     
         2 . The improving agent according to  claim 1 , wherein the lyase is chondroitinase ABC. 
     
     
         3 . The improving agent according to  claim 2 , wherein the neuropathic pain due to a hyperalgesic response is allodynia. 
     
     
         4 . The improving agent according to  claim 3 , wherein the neuropathic pain due to a hyperalgesic response is neuropathic pain caused by a central nervous disorder. 
     
     
         5 . The improving agent according to  claim 4 , wherein the central nervous disorder is a spinal cord injury. 
     
     
         6 . The improving agent according to  claim 1 , wherein the neuropathic pain due to a hyperalgesic response is allodynia. 
     
     
         7 . The improving agent according to  claim 1 , wherein the neuropathic pain due to a hyperalgesic response is neuropathic pain caused by a central nervous disorder. 
     
     
         8 . The improving agent according to  claim 2 , wherein the neuropathic pain due to a hyperalgesic response is neuropathic pain caused by a central nervous disorder. 
     
     
         9 . (canceled) 
     
     
         10 . The improving agent according to  claim 6 , wherein the neuropathic pain due to a hyperalgesic response is neuropathic pain caused by a central nervous disorder. 
     
     
         11 . The improving agent according to  claim 7 , wherein the central nervous disorder is a spinal cord injury. 
     
     
         12 . The improving agent according to  claim 8 , wherein the central nervous disorder is a spinal cord injury. 
     
     
         13 . The improving agent according to  claim 10 , wherein the central nervous disorder is a spinal cord injury. 
     
     
         14 . (canceled)